BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 9776707)

  • 21. Mice deficient in fas ligand (gld) or fas (lpr) show few alterations in granulopoiesis.
    Fecho K; Bentley SA; Cohen PL
    Cell Immunol; 1998 Aug; 188(1):19-32. PubMed ID: 9743554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous stimulation of Fas-mediated apoptosis and blockade of costimulation prevent autoimmune diabetes in mice induced by multiple low-dose streptozotocin.
    Jin Y; Qu A; Wang GM; Hao J; Gao X; Xie S
    Gene Ther; 2004 Jun; 11(12):982-91. PubMed ID: 15042121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of endogenous Fas (CD95/Apo-1) ligand in balloon-induced apoptosis, inflammation, and neointima formation.
    Matter CM; Chadjichristos CE; Meier P; von Lukowicz T; Lohmann C; Schuler PK; Zhang D; Odermatt B; Hofmann E; Brunner T; Kwak BR; Lüscher TF
    Circulation; 2006 Apr; 113(15):1879-87. PubMed ID: 16606788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
    Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
    J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TcR-alpha/beta(+) CD4(-)CD8(-) T cells in humans with the autoimmune lymphoproliferative syndrome express a novel CD45 isoform that is analogous to murine B220 and represents a marker of altered O-glycan biosynthesis.
    Bleesing JJ; Brown MR; Dale JK; Straus SE; Lenardo MJ; Puck JM; Atkinson TP; Fleisher TA
    Clin Immunol; 2001 Sep; 100(3):314-24. PubMed ID: 11513545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells.
    Modiano JF; Sun J; Lang J; Vacano G; Patterson D; Chan D; Franzusoff A; Gianani R; Meech SJ; Duke R; Bellgrau D
    Clin Immunol; 2004 Jul; 112(1):54-65. PubMed ID: 15207782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of grafted gld cells in athymic and euthymic recipients.
    Rosenblatt N; Hartmann KU; Loor F
    Immunology; 1995 Apr; 84(4):562-70. PubMed ID: 7790030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer.
    Zhang H; Yang Y; Horton JL; Samoilova EB; Judge TA; Turka LA; Wilson JM; Chen Y
    J Clin Invest; 1997 Oct; 100(8):1951-7. PubMed ID: 9329958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. gld/gld mice are unable to express a functional ligand for Fas.
    Ramsdell F; Seaman MS; Miller RE; Tough TW; Alderson MR; Lynch DH
    Eur J Immunol; 1994 Apr; 24(4):928-33. PubMed ID: 7512035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apoptosis provoked by the oxidative stress inducer menadione (Vitamin K(3)) is mediated by the Fas/Fas ligand system.
    Caricchio R; Kovalenko D; Kaufmann WK; Cohen PL
    Clin Immunol; 1999 Oct; 93(1):65-74. PubMed ID: 10497012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection of islet allografts transplanted together with Fas ligand expressing testicular allografts.
    Takeda Y; Gotoh M; Dono K; Nishihara M; Grochowiecki T; Kimura F; Yoshida T; Ohta Y; Ota H; Ohzato H; Umeshita K; Takeda T; Matsuura N; Sakon M; Kayagaki N; Yagita H; Okumura K; Miyasaka M; Monden M
    Diabetologia; 1998 Mar; 41(3):315-21. PubMed ID: 9541172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of Fas ligand as an effector molecule in corneal graft rejection.
    Stuart PM; Yin X; Plambeck S; Pan F; Ferguson TA
    Eur J Immunol; 2005 Sep; 35(9):2591-7. PubMed ID: 16114107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunological and pathological consequences of mutations in both Fas and Fas ligand.
    Weintraub JP; Godfrey V; Wolthusen PA; Cheek RL; Eisenberg RA; Cohen PL
    Cell Immunol; 1998 May; 186(1):8-17. PubMed ID: 9637760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B lymphocytes mediate Fas-dependent cytotoxicity in MRL/lpr mice.
    Bonardelle D; Benihoud K; Kiger N; Bobé P
    J Leukoc Biol; 2005 Nov; 78(5):1052-9. PubMed ID: 16204618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
    Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
    Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model.
    Nagata S
    J Hum Genet; 1998; 43(1):2-8. PubMed ID: 9609991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model.
    Fingleton B; Carter KJ; Matrisian LM
    Cancer Res; 2007 May; 67(10):4800-6. PubMed ID: 17510409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of Fas ligand in murine bone marrow NK cells by bacterial polysaccharides.
    Halaas O; Vik R; Espevik T
    J Immunol; 1998 May; 160(9):4330-6. PubMed ID: 9574536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fas-mediated apoptosis is involved in the elimination of gene-transduced hepatocytes with E1/E3-deleted adenoviral vectors.
    Okuyama T; Li XK; Funeshima N; Fujino M; Sasaki K; Kita Y; Kosuga M; Takahashi M; Saito H; Suzuki S; Yamada M
    J Gastroenterol Hepatol; 1998 Sep; 13 Suppl():S113-8. PubMed ID: 9792044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo.
    Shimizu M; Yoshimoto T; Nagata S; Matsuzawa A
    Biochem Biophys Res Commun; 1996 Nov; 228(2):375-9. PubMed ID: 8920922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.